SCHEMBL18485336

SCHEMBL18485336

CON(C)C(=O)[C@@H]1C[C@H](C(=O)O)CN(C(=O)OC(C)(C)C)C1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 1/20 0.43
DDB1 Q16531 1/20 0.39
CRBN Q96SW2 1/20 0.39
HPGD P15428 1/20 0.39
HSD17B10 Q99714 1/20 0.37
USP30 Q70CQ3 3/20 0.37
MEN1 O00255 1/20 0.36
ALDH1A1 P00352 1/20 0.36
MAPT P10636 1/20 0.36
KMT2A Q03164 1/20 0.36
JAK2 O60674 1/20 0.35
JAK1 P23458 1/20 0.35
USP2 O75604 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
RECQL P46063 1/20 0.35
EPHX1 P07099 1/20 0.35
RORC P51449 1/20 0.34
TACR1 P25103 1/20 0.34
CHRM2 P08172 1/20 0.33
CHRM1 P11229 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL278133 0.89 NR1H2 (0.45) NR1H2DDB1CRBNHPGDUSP30
SCHEMBL17913807 0.86 NR1H2 (0.43) NR1H2DDB1CRBNHPGDUSP30
SCHEMBL89062 0.85 NR1H2 (0.54) NR1H2HPGDHSD17B10MEN1ALDH1A1
SCHEMBL20220628 0.85 NR1H2 (0.54) NR1H2HPGDHSD17B10MEN1ALDH1A1
SCHEMBL57263 0.85 NR1H2 (0.54) NR1H2HPGDHSD17B10MEN1ALDH1A1
SCHEMBL23230817 0.83 NR1H2 (0.55) NR1H2DDB1CRBNHPGDUSP30
SCHEMBL29745515 0.83 NR1H2 (0.55) NR1H2DDB1CRBNHPGDUSP30
SCHEMBL2992998 0.83 NR1H2 (0.55) NR1H2DDB1CRBNHPGDUSP30
SCHEMBL31453954 0.83 NR1H2 (0.46) NR1H2DDB1CRBNHPGDUSP30
SCHEMBL19798975 0.83 NR1H2 (0.40) NR1H2DDB1CRBNHPGDUSP30

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9878981-B2 Method for producing heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2018-01-30 US disclosed
US-20170121286-A1 METHOD FOR PRODUCING HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-05-04 US disclosed
EP-3130581-A1 METHOD FOR PRODUCING HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2017-02-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170121286-A1 METHOD FOR PRODUCING HETEROCYCLIC COMPOUND REN, AGT, AGTR1 NR1H2 2394/4885DDB1 1380/4885CRBN 3528/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.